Evid Invest
Holders — by stockHoldings — by fund

Jones Hill Capital LP

Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-09-30 · filed with the SEC up to 45 days after quarter end · CIK 0002102314

$589.2M

disclosed book value

33

positions

11.9%

largest position share

Positions, as of 2026-09-30

top 33 of 33 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held

#IssuerSharesValue% of book
1BMRNBIOMARIN PHARMACEUTICAL INC1.2M$70.3M11.9%
2BCRXBIOCRYST PHARMACEUTICALS INC7.1M$59.0M10%
3TVTXTRAVERE THERAPEUTICS INC959,634$56.5M9.6%
4INDVINDIVIOR PHARMACEUTICALS INC1.5M$54.7M9.3%
5PHVSPHARVARIS N V987,637$31.3M5.3%
6CELCCELCUITY INC382,901$30.4M5.2%
7IONSIONIS PHARMACEUTICALS INC599,826$26.8M4.5%
8SUPNSUPERNUS PHARMACEUTICALS601,685$25.9M4.4%
9NUVBNUVATION BIO INC4.5M$25.1M4.3%
10VERAVERA THERAPEUTICS INC652,218$21.1M3.6%
11TRVITREVI THERAPEUTICS INC1.4M$20.7M3.5%
12BCAXBICARA THERAPEUTICS INC1.1M$19.8M3.4%
13RLMDRELMADA THERAPEUTICS INC5.2M$19.7M3.4%
14ABVXABIVAX SA142,558$14.1M2.4%
15ACRSACLARIS THERAPEUTICS INC2.5M$13.2M2.2%
16INSMINSMED INC106,528$12.2M2.1%
17NBIXNEUROCRINE BIOSCIENCES INC83,426$11.8M2%
18IMCRIMMUNOCORE HLDGS PLC384,278$11.6M2%
19ERASERASCA INC610,118$8.9M1.5%
20CAPRCAPRICOR THERAPEUTICS INC892,532$8.5M1.4%
21DNTHDIANTHUS THERAPEUTICS INC80,017$7.0M1.2%
22NGNENEUROGENE INC217,700$6.1M1%
23CRBPCORBUS PHARMACEUTICALS HLDGS886,428$6.0M1%
24TNXPTONIX PHARMACEUTICALS HLDG C563,739$5.5M0.9%
25SGMTSAGIMET BIOSCIENCES INC502,587$5.0M0.8%
26DYNDYNE THERAPEUTICS INC300,900$4.8M0.8%
27AVLNAVALYN PHARMACEUTICALS INC126,744$3.6M0.6%
28ATTOATTOVIA THERAPEUTICS INC182,295$3.1M0.5%
29PHATPHATHOM PHARMACEUTICALS INC276,830$2.0M0.3%
30LXEOLEXEO THERAPEUTICS INC593,737$2.0M0.3%
31OLMAOLEMA PHARMACEUTICALS INC206,397$1.8M0.3%
32TENXTENAX THERAPEUTICS INC122,169$230,8990%
33ALVOALVOTECH26,700$154,8600%

Source: SEC Form 13F-HR, reporting period 2026-09-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.